Yu Feng
5PUBLICATIONS
15CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (5)
Sort by Publication Date:
|Aug 11, 2025
Efficacy and Safety of Afatinib Plus Bevacizumab as First-Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial.Huiyang Shi, Miaohan Wang, Junling Li
|Aug 08, 2023
Efficacy and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer: A systematic review and meta-analysis.Yu Feng, Yunxia Tao, Haizhu Chen
|Nov 01, 2022
DLX2 Is a Potential Immune-Related Prognostic Indicator Associated with Remodeling of Tumor Microenvironment in Lung Squamous Cell Carcinoma: An Integrated Bioinformatical Analysis.Liling Huang, Tongji Xie, Fuqiang Zhao
|Sep 09, 2022
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non-small cell lung cancer: A real-world study.Yu Feng, Liling Huang, Haohua Zhu
|Aug 23, 2021
Circulating tumor cells (CTCs)/circulating tumor endothelial cells (CTECs) and their subtypes in small cell lung cancer: Predictors for response and prognosis.Hao-Hua Zhu, Yu-Tao Liu, Yu Feng
Pageof 1
Frequent Collaborators
4 joint publications
Xingsheng Hu
3 joint publications
Haohua Zhu
3 joint publications
Yuankai Shi
2 joint publications
Yuankai Shi
1 joint publications
Tong-Mei Zhang
1 joint publications
Pu-Yuan Xing
1 joint publications
Liling Huang
1 joint publications
Tongji Xie
1 joint publications
Fuqiang Zhao
1 joint publications
Le Tang
